我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
22
3 进行中
药物批准
1
批准总数
监管机构
监管机构数
成立时间
1935
进行中（未招募）
3
13.6%
已完成
17
77.3%
终止
2
9.1%
EMA
European Medicines Agency
- Avanzanite Bioscience raised €32 million in Series A funding from MVM Partners to expand its pan-European rare disease commercialization platform across 32 countries. - The company reported record Q3 2025 performance with revenue tripling year-over-year and growing over 20% quarter-on-quarter since launching three orphan drugs. - Avanzanite's integrated business model addresses Europe's fragmented healthcare landscape by coordinating pricing, reimbursement, and regulatory strategies for rare disease therapies. - The funding will support new product partnerships, asset acquisitions, and scaling of regulatory and commercial operations to improve patient access to orphan medicines.
